Meitheal Pharmaceuticals Announces Membership of the Association for Accessible Medicines

CHICAGO, May 02, 2022–(BUSINESS WIRE)–Meitheal Pharmaceuticals (“Meitheal”), a fully integrated generic injectables company based in Chicago, Illinois, today announced that it has joined the Association for Accessible Medicines ( AAM), the trade association representing the generics and biosimilars industry. The AAM works to ensure greater accessibility to generic and biosimilar medicines and to advance policies that promote the sustainability of the accessible medicine industry.

“We are proud to partner with AAM to support our mission to fill important gaps in healthcare with an affordable and diverse line of generic injectables,” said Tom Shea, Chief Executive Officer of Meitheal Pharmaceuticals. “We look forward to working together towards our shared goal of getting safe, effective and more affordable medicines out of the lab and into the hands of the people who need them.”

“Meitheal’s active engagement in the AAM makes our voice even stronger and more effective as we advocate on behalf of the generics industry and its mission to ensure that our quality, safe, effective and affordable medicines are accessible to American patients,” said Dan Leonard, AAM’s Chief Executive Officer. “We are pleased to welcome Tom Shea’s participation on our Board of Directors alongside his industry peers.”

Meitheal primarily specializes in the development, manufacture, supply and sale of generic injectable pharmaceutical products, with 36 FDA-approved products covering indications for anti-infective, oncolytic and intensive care. Additionally, Meitheal has an expanding product portfolio and a robust pipeline, including single-dose and multi-dose vials, ready-to-use prefilled syringes and premixed sachets. At the end of March 2022, Meitheal had 49 products in the research and development phase, 24 products were under review by the United States Food and Drug Administration (FDA), and 16 products were scheduled to be launched in 2022.


Since 2017, Meitheal Pharmaceuticals has filled critical gaps in the US healthcare market by providing affordable, high-quality generic injectables. Our diverse product line – from antibiotics, blood thinners and muscle relaxants to drugs used in chemotherapy – represents practical solutions for countless patients across the country, as well as Meitheal’s commitment to their care. Based in Chicago, Illinois, our daily goal is to produce quality and ensure affordability, using the traditional Irish guiding principle for which we are named – Meitheal (Mee hall): working together towards a common goal, for the greater good.

Learn more about who we are and what we do at


The AAM is driven by the belief that access to safe, quality and effective medicine has a profound impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy. The AAM represents manufacturers and distributors of finished generic pharmaceutical products and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generics industry. Generic pharmaceuticals account for 90% of prescriptions dispensed in the United States, but only 18% of total drug spending.


The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source of information on the safety and effectiveness of more affordable alternatives to expensive brand-name biologic drugs. Areas of interest include training public and health experts, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at

See the source version on


Meitheal Pharmaceuticals, Inc.
Anne Renick, Vice President of Corporate Strategy
224 443 4520
[email protected]

Andrew B. Reiter